Stem Cell Transplant or Cellular Therapy - Allogeneic

- **IRB# 10146**
  Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high risk myelodysplastic syndrome.

- **IRB# 17622**
  Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

- **IRB# 16995**
  Tests the drug PRO140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

- **IRB# 16189**
  Phase 1/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.

- **IRB# 18142**
  Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidentical transplant (HATCY).

- **IRB# 16943**
  BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

- **IRB# 18301**
  Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

6/6/2018